Mahmut Kaya

Mahmut Kaya

Auto-generated profile, based on publicly available information

Mahmut Kaya

Department of Ophthalmology, Dokuz Eylul University School of Medicine, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
BYBetul Akbulut Yagci
Betul Akbulut Yagci
FAFerdane Atas
Ferdane Atas
MKMahmut Kaya
Mahmut Kaya
GAGul Arikan
Gul Arikan
Purpose: To report a case of bilateral acute iris transillumination (BAIT) in association with coronavirus disease 2019 (COVID-19). Case report: A 44-year-old woman patient presented with decreased visual acuity, pain, photophobia, and redness in both eyes. The patient reported that she had recent close contact with severe acute respiratory syndrome - coronavirus-2 (SARS-CoV-2) case; also, she mentioned that she was hospitalized for bilateral pneumonia for 14 days. On examination, visual acuity of both eyes was 20/40. Slit-lamp biomicroscopy showed bilateral pigment deposition on the corneal endothelium, 4+ pigment dispersion in the anterior chamber, iris depigmentation with iris transillumination defects. Intraocular pressure was measured as 32 mmHg in right eye and 38 mmHg in left eye. The patient was started on bilaterally topical anti-inflammatory and anti-glaucomatous therapy. Conclusion: It is important to keep in mind that ocular manifestations associated with COVID-19 may include rare entities such as BAIT.

1 January 2018 in Korean Journal of Ophthalmology
Verified
Journal Article
Open access
MKMahmut Kaya
Mahmut Kaya
EKEyyup Karahan
Eyyup Karahan
TOTaylan Ozturk
Taylan Ozturk
NKNilufer Kocak
Nilufer Kocak
SKSuleyman Kaynak
Suleyman Kaynak
Kaya M, et al. Korean J Ophthalmol. 2018 Jun;32:e40. https://doi.org/10.3341/kjo.2017.0117

12 May 2020 in Eye
Verified
Journal Article
Open access
PDF file
MKMahmut Kaya
Mahmut Kaya
NKNilufer Kocak
Nilufer Kocak
TOTaylan Ozturk
Taylan Ozturk
VBVolkan Bolluk
Volkan Bolluk
ZAZiya Ayhan
Ziya Ayhan
SKSuleyman Kaynak
Suleyman Kaynak
Purpose: To assess the 12-month efficacy and safety of simultaneously administered intravitreal dexamethasone implant (DEX implant) and ranibizumab (simultaneous double protocol) injections in comparison with ranibizumab monotherapy as the first-line treatment of diabetic macular oedema (DMO). Methods: Prospective, consecutive, clinical interventional study. Patients were randomized into two groups: 24 naive DMO patients (34 eyes) who received simultaneous double-protocol therapy and 22 DMO patients (34 eyes) who received ranibizumab monotherapy were included. Monthly ranibizumab (0.5 mg) was administered for the first 6 months and later on, an as-needed treatment basis. DEX implant injection was performed at any time during the loading dose of the three consecutive monthly injections of ranibizumab, and with as-needed reinjections of ranibizumab from 6th month onwards. Change in visual acuity was the primary efficacy endpoint. Secondary efficacy endpoints were a gain of ≥15 letters and a change in the central foveal thickness. Results: Mean BCVA increased from baseline to month 12 in the simultaneously double-protocol therapy group compared with the ranibizumab monotherapy group (21.6 versus 9.6 letters [P < 0.001]). The corresponding proportions of eyes gaining ≥15 letters were 60% versus 29.4% (P < 0.0001). Moreover, the mean reductions in the central foveal thickness were 413 versus 282 µm (P = 0.001). At 12 month, the simultaneous double-protocol therapy decreased a significant number of foveal cysts and subfoveal neuroretinal detachment compared with those by ranibizumab monotherapy. Conclusions: The simultaneous addition of DEX implant at any time during the three monthly loading doses of ranibizumab in patients with DMO significantly improved the visual outcomes and revealed superior anatomic outcomes than those with the ranibizumab monotherapy.

1 January 2017 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
PDF file
MKMahmut Kaya
Mahmut Kaya
AOAyhan Ozyurt
Ayhan Ozyurt
NKNilufer Kocak
Nilufer Kocak
PAPınar Akan
Pınar Akan
OCOzlem Gursoy Calan
Ozlem Gursoy Calan
SKSuleyman Kaynak
Suleyman Kaynak
Aim: The aim of the study was to evaluate the macular pigment optical density (MPOD) levels in patients with wet age-related macular degeneration (AMD), dry AMD, and also in healthy controls. Settings and Design: This study was conducted at Department of Ophthalmology, and the study design was a prospective study. Patients and Methods: Forty-eight patients with wet AMD, 51 patients with dry AMD, and 50 controls were included in the study. All patients were naive to both previous lutein or zeaxanthin administration and any previous intravitreal injections. Fundus reflectance (VISUCAM 500, reflectance of a single 460 nm wavelength) was used to measure the MPOD levels. Three groups were compared regarding age, gender, serum lutein, and zeaxanthin concentrations as well as MPOD levels. Results: Serum lutein and zeaxanthin levels were significantly higher in control group when compared with wet AMD (Group 1) and dry AMD (Group 2) (P = 0.001 and P< 0.001, respectively). Mean MPOD was found to be similar in all of the three study subgroups (P = 0.630). However, maximum MPOD was significantly higher in control group when compared with Group 1 and 2 (P = 0.003). There was no correlation between serum lutein or zeaxanthin concentrations and mean MPOD levels (P = 0.815, r = 0.014 and P = 0.461, r = 0.043, respectively), but there was a weak correlation between serum zeaxanthin concentration and maximum MPOD level (P = 0.042, r = 0.124). Maximum MPOD level was found to be correlated with the level of AMD (Group 1, 2, and 3; r = 0.184, P = 0.041). Conclusion: Maximum MPOD level was found to be lower in patients with AMD when compared with control cases. Mean MPOD and maximum MPOD levels were similar in wet and dry AMD Groups. These results can be applied clinically keeping in mind that MPOD measurements with one wavelength reflectometry may not be completely reliable.

2 July 2020 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
MKMahmut Kaya
Mahmut Kaya
FAFerdane Atas
Ferdane Atas
ZGZeynep Gulsum Guc
Zeynep Gulsum Guc
IOIlhan Oztop
Ilhan Oztop
IDIsmet Durak
Ismet Durak
ASAli Osman Saatci
Ali Osman Saatci
Purpose: To evaluate the characteristics of macular retinal and subfoveal choroidal changes in patients already on taxane-based therapy by the help of spectral domain optical coherence tomograpy (SD-OCT) and determine the incidence of taxane- related cystoid macular edema (CME). Materials and Methods: In this cross-sectional case-control study, 202 patients who received taxane-based therapy due to treatment of various cancer and age and sex-matched 200 healthy control subjects were examined. Only patients who received at least 4 cycles of taxane-based therapy were taken into consideration for the taxane group. Taxane-based therapy was further divided into two subgroups; paclitaxel group (149 patients) and docetaxel group (53 patients). Central macular thickness (CMT) and subfoveal choroidal thickness (CCT) were measured just once during their ongoing chemotherapy using SD-OCT and enhanced-depth imaging (EDI) OCT by Heidelberg OCT by a single examiner. Results: Patients received a median of 7 cycles (range 4 to 26) of paclitaxel or docetaxel and received a total cumulative dose of 852.81 ± 368.82 mg/m2 (range, 300 to 2310 mg/m2). Though the mean CMT was significantly thicker in the taxane group (224.9 ± 28.4 µm) than the healthy control group (215.9 ± 19.7 µm), there was no statistically significant difference between the paclitaxel (225.3 ± 28.2 µm) and docetaxel (224.2 ± 20.1 µm) groups. On the other hand, the central subfoveal choroidal thickness (CCT) was not statistically significant different between the taxane versus control eyes and paclitaxel versus docetaxel patients. Taxane- related CME was detected only in one patient on paclitaxel. Overall, incidence of taxane- related maculopathy was 0.5% (1/202) of all patients in the taxane group. Conclusion: In our group of taxane receiving patients, incidence of taxane- related CME was 0.5%. In light of our study, we believe that clinicians should be alert on the occurence of taxane -related CME and carefully scrutinize the patients whenever any suspicion is arisen.

1 December 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
FAFerdane Atas
Ferdane Atas
MKMahmut Kaya
Mahmut Kaya
ASAli Osman Saatci
Ali Osman Saatci
To report a case with acute posterior multifocal placoid pigment epitheliopathy (APMPPE)-like presentation following the first dose of BNT162b2 COVID-19 vaccinationAn otherwise healthy 45-year-old ...